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ABSTRACT
Objective: We sought to investigate the impact of self-reported fasting duration times on the lipid 
profile results and its impact on the cardiovascular risk stratification and metabolic syndrome 
diagnosis. Subjects and methods: We analyzed data from all consecutive individuals evaluated in a 
comprehensive health examination at the Hospital Israelita Albert Einstein from January to December 
2015. We divided these patients in three groups, according to the fasting duration recalled (< 8h, 
8-12h and > 12h). We calculated the global cardiovascular risk and diagnosed metabolic syndrome 
according to the current criteria and estimated their change according to fasting duration. Results: 
A total of 12,196 (42.3 ± 9.2 years-old, 30.2% females) patients were evaluated. The distribution 
of cardiovascular risk was not different among groups defined by fasting duration in both men 
and women (p = 0.547 for women and p = 0.329 for men). Similarly, the prevalence of metabolic 
syndrome was not influenced by the fasting duration (p = 0.431 for women and p = 0.166 for men). 
Conclusion: Self-reported fasting duration had no significant impact on the lipid profile results, 
including triglyceride levels. Consequently, no changes on the cardiovascular risk stratification using 
the Framingham risk score nor changes on the prevalence of metabolic syndrome were noted. Arch 
Endocrinol Metab. 2018;62(2):187-92
Keywords
Triglycerides; cardiovascular risk; metabolic syndrome; fasting
INTRODUCTION
C urrent guidelines on screening for cardiovascular risk rely on the measurement of plasma 
cholesterol levels as part of the initial risk stratification 
(1-3). Those guidelines also recommend that the lipid 
panel measurement should be performed after an 8- to 
12-hour fast. This fasting request is proposed as a way 
to eliminate any interference of the postprandial lipid 
levels, particularly for triglycerides, and to allow the 
use of previously validated cut-offs for diagnosis and 
management of dyslipidemia (3,4). However, this long 
fasting period may be cumbersome and may lead to 
important logistic difficulties to patients. 
Interestingly, prior evidence suggests that the lipid 
profile variability is relatively small in healthy individuals 
(5,6). Other groups have already analyzed the interference 
of fasting on the lipid profile, and their results suggest 
that less than 12-hour fasting may offer important logistic 
advantages with minimal impact on the lipid panel results 
or cardiovascular risk stratification (7-9).
Despite those previous results on the lipid profile 
variability, few studies (10,11) have evaluated the 
impact of the fasting duration on cardiovascular risk 
stratification or metabolic syndrome diagnosis. Such 
information is necessary as the clinical relevance of the 
lipid profile variability mainly depends on its effects 
on cardiovascular risk stratification and, hence, on 
the clinical decision-making process. Therefore, in 
the present study we sought to investigate the impact 
of self-reported fasting duration time on the lipid 
profile results and its impact on the cardiovascular risk 
stratification and metabolic syndrome diagnosis.
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SUBJECTS AND METHODS
We selected all consecutive individuals evaluated at 
the Hospital Israelita Albert Einstein from January 
to December 2015. This evaluation was part of an 
executive checkup program paid by the employers from 
their organizations. The protocol includes extensive 
clinical and laboratory evaluations.
The Ethical Committee of the Hospital Israelita 
Albert Einstein approved this study and the consent 
form was waived as the research is based on database 
analysis and no additional patient contact was needed.
Participants were questioned about previous 
presence of dyslipidemia, systemic arterial hypertension 
(previous diagnosis, use of anti-hypertensive medicines 
or measured blood pressure ≥ 140/90 mmHg), diabetes 
(previous use of medicines for diabetes or fasting 
glycemia > 126 mg/dL) and smoking (consumption 
of at least one cigarette per day within the last 30 
days). Body mass index (BMI) was measured using 
the weight/height2 (kg/m2) formula. The abdominal 
circumference was measured by a trained nutritionist 
and was considered abnormal when above 94 cm for 
men and 80 cm for women. 
We included patients between 20 and 80 years of 
age and excluded those taking statins or with liver 
problems. 
When the patients made the appointment for the 
comprehensive health examination, they were oriented 
to fast for at least 12 hours. On the day of the exam, 
they were asked about how long they have been 
fasting. Independently of the fasting time, all exams 
were collected. Therefore, the patients were analyzed 
considering the period of time they self-reported they 
were fasting. We divided these patients in three groups, 
according to self-reported fasting duration: less than 8 
hours fasting, between 8 and 12 hours and more than 
12 hours fasting.
We calculated the general cardiovascular risk, 
considering gender, age, systolic blood pressure, 
smoking, presence of diabetes, use of anti-hypertensive 
agents, HDL-cholesterol levels and total cholesterol 
levels. If the risk was lower than 10% in 10 years, it was 
considered low risk; between 10 and 20%, intermediate 
risk and higher than 20%, high risk for cardiovascular 
events in 10 years (12). This score calculates the risk 
of coronary death, myocardial infarction, coronary 
insufficiency, angina, ischaemic stroke, hemorrhagic 
stroke, transient ischemic attack, peripheral artery 
disease and heart failure in 10 years.
The diagnosis of metabolic syndrome was made 
if waist circumference was abnormal (≥ 94 cm in 
men and 80 cm in women) and at least two of these 
four elements were impaired: HDL-cholesterol, 
triglycerides, glycemia and blood pressure (13). 
The measurement of lipoproteins (total cholesterol, 
HDL-C and triglycerides) was performed in automated 
equipment VITROS 5600® Ortho Clinical Diagnostics 
by dry chemical colorimetric method. The LDL-C was 
calculated by Fridewald formula for triglycerides for 
concentrations up to 250 mg/dL. For values greater 
than 250 mg/dL, direct LDL-C was performed in 
automated equipment VITROS 5600® Ortho Clinical 
Diagnostics by endpoint methodology. The LDL-C 
calculated loses correlation when compared to the 
gold standard that is ultracentrifugation. The higher 
the triglyceride value, the worst is this relationship 
(14). For this reason we use the calculation for values 
up to 250 mg/dL keeping the routine used by Albert 
Einstein Hospital laboratory.
Statistical analysis
Continuous variables are presented as means and 
standard deviation or medians and quartiles, as 
appropriate, and compared using one-way ANOVA or 
Kruskal-Wallis test. Categorical variables are presented 
as absolute numbers and proportions, and compared 
using chi-square test. 
In order to accommodate the significant difference 
in the distribution of gender across fasting duration, 
different cardiovascular risk calculators and differences 
in the definition of metabolic syndrome, we chose 
to perform a gender-stratified analysis across fasting 
duration groups. 
Additionally, in order to adjust for the potential 
confounding effect of age, gender and waist 
circumference across the fasting duration groups, we 
chose to perform a multiple linear regression analysis 
on triglyceride levels.
A level of significance of 0.05 was used. All analysis 
were performed using Stata version 13.0 (StataCorp, 
USA).
RESULTS
We included 12,196 patients that were divided in 
three groups according to the self-reported fasting 
time. The baseline characteristics of these groups are 
shown in Table 1. Due to the large sample size, almost 
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all information was statistically different between the 
groups, though the absolute differences were small. 
For triglycerides, a small, albeit significant, increase 
was noted with longer fasting duration. However, after 
adjustment for the confounding effects of age, gender 
and waist circumference, no significant difference in 
triglyceride levels was observed (< 8 hours vs 8-12 
hours: p = 0.114; < 8 hours vs > 12 hours: p = 0.220). 
Additionally, most risk factors were associated with 
triglyceride levels, though the median fasting duration 
was not different across triglycerides strata (Table 2). 
The small changes in the lipid profile across the fasting 
Table 1. Baseline characteristics stratified according to fasting duration
Total (n = 12,196) Less than 8 h fasting (n = 1,829)
Between 8 and 12 h 
fasting (n = 5,515)
More than 12 h fasting 
(n = 4,852) p
Male 8,514 (69.8) 949 (52) 4,031 (73.1) 3,534 (72.8) < 0.001
Age (y) 42.3 ± 9.2 41.4 ± 9.0 42.5 ± 9.0 42.2 ± 9.4 < 0.001
BMI (kg/m2) 26.3 ± 4.2 26.0 ± 4.5 26.2 ± 4.1 26.5 ± 4.2 < 0.001
Waist circumference (cm) 91 ± 15.0 89 ± 13.6 91 ± 12.5 92 ± 17.9 < 0.001
SBP (mmHg) 115.6 ± 12.0 114.6 ± 12.6 115.7 ± 12.0 115.9 ± 11.9 < 0.001
DBP (mmHg) 76.2 ± 8.2 76.4 ± 8.7 76.0 ± 8.1 76.3 ± 8.0 0.096
Total Cholesterol (mg/dL) 191.8 ± 34.4 193.6 ± 35.3 190.5 ± 34.5 192.7 ± 34.0 < 0.001
LDL-c (mg/dL) 118.5 ± 31.4 117.9 ± 32.3 118.1 ± 31.4 119.1 ± 31.1 0.236
HDL-c (mg/dL) 48.8 ± 14.0 51.8 ± 15.5 48.3 ± 13.6 48.2 ± 13.7 < 0.001
Tryglicerides (mg/dL) 124.3 ± 83.7 119.4 ± 82.4 121.6 ± 76.0 129.3 ± 83.7 < 0.001
Glucose (mg/dL) 87.0 ± 13.1 82.0 ± 12.6 87.9 ± 11.4 87.8 ± 14.5 < 0.001
HbA1c (%) 5.40 ± 0.5 5.37 ± 0.5 5.38 ± 0.5 5.42 ± 0.6 < 0.001
Diabetes 178 (1.5) 19 (1.0) 84 (1.6) 75 (1.6) 0.265
Hypertension 1331 (10.9) 175 (9.6) 607 (11.0) 549 (11.3) 0.119
Smoking 1049 (8.6) 175 (9.6) 447 (8.1) 427 (8.8) 0.029
Fasting duration (h)* 11.7 (10.2-12.4) 5.2 (4.0-6.2) 11.2 (10.3-11.6) 12.6 (12.2-13.2) 0.001
Values are mean ± SD or n (%).
* Median and quartiles.
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; LDL-c: low-density lipoprotein cholesterol; HDL-c: high-density lipoprotein cholesterol; HbA1c: glycated 
hemoglobin.
Table 2. Baseline characteristics stratified according to triglycerides levels
Tg < 150 mg/dL (n = 9,131) Tg 150 – 400 mg/dL (n = 2,927) Tg > 400 mg/dL (n = 124) p
Male 5,963 (65.31) 2,430 (83.02) 117 (94.35) < 0.001
Age (y) 41.9 ± 9.3 43.4 ± 8.8 42.8 ± 8.2 < 0.001
BMI (kg/m2) 25.7 ± 4.0 28.2 ± 4.2 28.5 ± 3.8 < 0.001
Waist circumference (cm) 88.8 ± 15.4 97.5 ± 11.8 99.2 ± 10.1 < 0.001
SBP (mmHg) 114.2 ± 11.7 119.6 ± 12 123.6 ± 12.0 < 0.001
DBP (mmHg) 75.2 ± 8 79.1 ± 8 81.3 ± 8.2 < 0.001
Total Cholesterol (mg/dL) 185.5 ± 32 209.9 ± 34 232.2 ± 38.5 < 0.001
LDL-c (mg/dL) 115.8 ± 30.5 127.5 ± 32.1 100.6 ± 35.4 < 0.001
HDL-c (mg/dL) 51.5 ± 13.8 41.2 ± 11.1 31.3 ± 7.4 < 0.001
Glucose (mg/dL) 85.6 ± 10 90.7 ± 18.3 98.7 ± 30.3 < 0.001
HbA1c (%) 5.4 ± 0.4 5.5 ± 0.7 5.8 ± 1.2 < 0.001
Diabetes 90 (1.0) 79 (2.7) 9 (7.3) < 0.001
Hypertension 826 (9.1) 481 (16.4) 23 (18.6) < 0.001
Smoking 710 (7.8) 324 (11.1) 14 (11.3) < 0.001
Fasting duration (h)* 11.7 (10.1-12.4) 11.8 (10.5-12.5) 11.5 (10-12.3) < 0.0001
Values are mean ± SD or n (%).
* Median and quartiles.
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; LDL-c: low-density lipoprotein cholesterol; HDL-c: high-density lipoprotein cholesterol; HbA1c: glycated 
hemoglobin.
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duration groups did not impact the overall distribution 
of cardiovascular risk irrespective of gender (Figure 1 – p 
= 0.547 for women and p = 0.329 for men). Similarly, 
the prevalence of metabolic syndrome was not influenced 
by the fasting duration in both genders (Figure 2 – 
p = 0.431 for women and p = 0.166 for men). 
DISCUSSION
We have shown that the self-reported fasting time had no 
significant impact on the lipid profile results. Consequently, 
no changes on the cardiovascular risk stratification using 
the Framingham risk score nor changes on the prevalence 
of metabolic syndrome were noted. 
A recent review from the American College of 
Cardiology (15) has discussed the use of fasting or non-
fasting samples depending on the question we need to 
answer. Although they do not provide extensive data to 
support the idea, they suggest that non-fasting samples 
are sufficient to estimate baseline cardiovascular risk in 
primary prevention and to define metabolic syndrome. 
Our findings provide robust real life data to support 
the expert opinion of this document, by addressing this 
issue in a large population of primary prevention adults 
undergoing a comprehensive heath examination.
Fasting has always been recommended prior to 
collecting serum lipid profile as the postprandial state 
is associated with a significant increase in triglycerides 
levels. As triglycerides are included in the Friedewald 
equation for calculating LDL-cholesterol levels, those 
changes in triglycerides levels could potentially affect 
the estimation of LDL-c and, therefore, impact the 
cardiovascular risk stratification. However, recent 
reports suggest that the impact of usual meals on 
triglyceride levels might be lower than previously 
estimated by fat tolerance tests. Thus, those reports 
agree that fasting prior to lipid profile evaluation might 
not be needed for most individuals (6,9,16). 
Despite those recommendations, experts have 
proposed new cut-points for these exams when 
performed in non-fasting scenarios. A recent study 
from the Women’s Health Study has determined a cut-
Figure 2. Metabolic syndrome prevalence according to fasting duration in women (A) and men (B).
Figure 1. General cardiovascular risk according to fasting duration in women (A) and men (B).
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off for triglycerides of 175 mg/dL when predicting 
cardiovascular risk using non-fasting samples (7). 
Similarly, the American College of Cardiology has 
established a threshold of 200 mg/dL for triglycerides 
when defining metabolic syndrome in a non-fasting 
state (15). Those recommendations contrast with 
the real life findings of our study, where the fasting 
duration did not significantly impact the lipid profile 
or the estimation of cardiovascular risk and metabolic 
syndrome based on it. 
Since the need of an 8 to 12 hour fasting impacts 
on the logistic of laboratory centers, the recent 
recommendations, corroborated by our current 
findings may facilitate the organization of laboratory 
services and add comfort to patients. It would allow 
distributing the patients’ appointment throughout the 
day, avoiding long waiting hours in the morning, as 
well as increasing the overall laboratory capacity with 
the distribution of tests throughout the day. 
Our study must, however, be read within the context 
of its design. First, we considered the fasting time 
recalled by the patients. It is probable that it was not 
exactly the same as the period that it really happened. 
However, it is difficult to find a way to measure this 
period without trusting the patient memory and all 
data on this subject considers the self-reported time. 
Not only that, patient recall of the last meal is the 
standard of care in real life. Second, the majority 
of our patients had low cardiovascular risk, which 
implies that the lipid profile is better and less likely 
to be affected by the fasting duration. Nonetheless, 
the main point of our findings is to improve patient’s 
adherence, especially those testing for an initial lipid 
profile or for first global cardiovascular risk assessment 
in a check-up unit. Also, we didn’t measure the lipid 
profile from the same patient with different fasting 
durations. Although it could generate some difference 
on the results, we understand that our population is 
homogeneous and the results from the group could 
be extrapolated to each individual. When analyzing 
the data, we could see that there were mild differences 
between the different fasting duration groups. It 
seems that older people with more comorbities (e.g. 
diabetes) are more likely to respect the fasting time, 
probably because they are more used to collect exams. 
Notwithstanding, these differences did not impact 
in our results and the guidance of non-fasting would 
be of great value for these patients in order to avoid 
hypoglycemia risk.
In conclusion, fasting does not impact the lipid 
profile testing in a comprehensive health examination, 
considering that the main purpose of this testing would 
be determining the global cardiovascular risk and 
metabolic syndrome diagnosis.
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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